Journey Medical Corporation (DERM)
NCM · Healthcare · Drug Manufacturers - Specialty & Generic
Closing price as of 2026-09-11 · Source: TEK2day Finance
Key Metrics
About Journey Medical Corporation
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris. It also provides Zilxi, a topical minocycline treatment for inflammatory lesions of rosacea; Emrosi for the treatment of inflammatory lesions of rosacea; Exelderm cream and solution for the treatment of fungal skin infections; and Targadox, an oral doxycycline drug for adjunctive therapy for severe acne, as well as Luxamend, a water-based emulsion formulated to provide a moist healing environment for superficial wounds; minor cuts or scrapes; dermal ulcers; donor sites; first- and second-degree burns, including sunburns; and radiation dermatitis. The company was formerly known as Coronado Dermatology, Inc. Journey Medical Corporation was incorporated in 2014 and is headquartered in Scottsdale, Arizona.
Quarterly Financials
| Metric | 2025-09-30 | 2025-12-31 | 2026-03-31 | 2026-06-30 |
|---|---|---|---|---|
| Revenue | 17.6M | 16.1M | 16.0M | 18.5M |
| Gross Profit | 11.9M | 10.6M | 9.7M | 12.4M |
| Operating Income | (1.5M) | (443K) | (1.5M) | 456K |
| Net Income | (2.3M) | (1.2M) | (2.2M) | (312K) |
| Diluted EPS | $-0.09 | N/A | $-0.08 | $-0.01 |
Annual Financials
| Metric | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|---|
| Revenue | 73.7M | 79.2M | 56.1M | 61.9M |
| Gross Profit | 42.9M | 56.3M | 35.3M | 40.9M |
| Operating Income | (27.5M) | 1.1M | (18.2M) | (8.2M) |
| Net Income | (29.6M) | (3.9M) | (14.7M) | (11.4M) |
| Diluted EPS | $-1.69 | $-0.21 | $-0.72 | N/A |